ADmit Therapeutics has received an investment of 497.652$ from the ADDF Diagnostics Accelerator for the development of its early Alzheimer’s disease diagnostic test in blood samples. The Diagnostics Accelerator is a research initiative that seeks to accelerate the development of affordable and accessible biomarkers to diagnose Alzheimer's disease and related dementias, and advance the development of more targeted treatments. To learn more about the initiative visit the website at: AlzDiscovery.org/accelerator.
ADmit Therapeutics is a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL), located in Barcelona, which has been granted by Spanish and European grants, and has received private investments from Ship2B, GENESIS Biomed, BStartup10 and other investors since its inception at the end of 2017.
An important grant for our development plan along 2020.
This grant will allow us to get access to Scandinavian Biobanks
Grant for covering the 70% of salary of our postdoc Marta Blanch for three years (2020-2022).
We present our project in the DemoDay in La Salle Technova, where Ship2B impulse with big corporates.
Finalists in the Investment Forum from ACCIÓ 2018!
We have assisted to the IE Venture Network Area 31 in Madrid.
ADmit Therapeutics selected in the MedTeX programme organized by Barcelona Scientific Park.
The new EU IVD Regulation has finally been adopted on April 5th 2017 and ADmit Therapeutics has already drawn the development plan according to this new Regulation.
ADmit Therapeutics has been created, acquiring a license agreement with IDIBELL and University of Barcelona to develop a test for an early AD detection.